Skip to content

US · KYTX · BIOTECHNOLOGY

Kyverna Therapeutics, Inc. (KYTX) intrinsic value and stock valuation

$4.26as of 2026-11-21 · Mkt cap 483.93M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kyverna Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values KYTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KYTX’s statements →

Kyverna Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Emeryville, CA 94608 kyvernatx.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-161.31M
20212025
Free cash flow
-$-153.72M
20212025
Total equity
$232.3M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$7.03M$5.66M
Operating income-$-169.83M-$-142.6M-$-62.41M-$-29.38M-$-26.35M
Net income-$-161.31M-$-127.48M-$-60.37M-$-28.89M-$-26.35M
EPSd-$-3.64M-$-3.33M-$-89.62K-$-1.12M-$-1.02M
Operating cash flow-$-153.71M-$-114.25M-$-52.41M-$-36.11M-$-22.16M
Capital expenditure-$-10K-$-2.21M-$-620K-$-770K-$-1.29M
Free cash flow-$-153.72M-$-116.45M-$-53.03M-$-36.88M-$-23.44M
Total assets$293.8M$304.6M$75.2M$66.9M$85.5M
Total debt$29M$8.24M$9.08M$10.6M$5.55M
Net debt-$-95.06M-$-88.38M-$-25.57M-$-27.17M-$-70.51M
Total equity$232.3M$266.6M$49.2M$46.7M-$-46.25M
Cash and short-term investments$279.3M$286M$57.5M$51.3M$76.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$7.03M$5.66M
Cost of revenue$0.00$2.13M$1.71M$0.00$0.00
Gross profit$0.00-$-2.13M-$-1.71M$7.03M$5.66M
Research and development expenses$133.7M$112.5M$48.2M$28.4M$25.9M
Selling, general and administrative expenses$36.1M$30.1M$12.5M$8.01M$6.15M
Other expenses$0.00-$-2.13M$0.00$0.00$0.00
Operating expenses$169.8M$140.5M$60.7M$36.4M$32M
Cost and expenses$169.8M$142.6M$62.4M$36.4M$32M
Interest income$9.09M$15.4M$2.28M$560K$0.00
Interest expense$490K$140K$190K$70K$0.00
Depreciation and amortization$1.8M$2.13M$1.71M$1.05M$590K
Ebitda-$-159.02M-$-125.2M-$-58.47M-$-27.78M-$-25.76M
Operating income-$-169.83M-$-142.6M-$-62.41M-$-29.38M-$-26.35M
Total other income/expenses, net$8.52M$15.1M$2.04M$490K-$0.00
Income before tax-$-161.31M-$-127.48M-$-60.37M-$-28.89M-$-26.35M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-161.31M-$-127.48M-$-60.37M-$-28.89M-$-26.35M
Weighted average shares outstanding$44.3M$38.3M$673.6M$25.8M$25.8M
Weighted average diluted shares outstanding$44.3M$38.3M$673.6M$25.8M$25.8M
Balance sheet
20252024202320222021
Cash and short-term investments$279.3M$286M$57.5M$51.3M$76.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$283M$290.6M$60.7M$53.3M$77.1M
Property, plant and equipment, net$5.42M$10.7M$10.6M$12.4M$7.81M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10.9M$15.9M$14.5M$13.7M$8.4M
Total assets$293.8M$304.6M$75.2M$66.9M$85.5M
Accounts payable$5.31M$4.62M$4.36M$1.45M$770K
Short-term debt$3.97M$3.94M$2.92M$2.28M$810K
Deferred revenue$0.00$0.00$0.00$0.00$6M
Total current liabilities$36.5M$33.8M$19.9M$12M$15.9M
Long-term debt$25.1M$4.3M$6.16M$8.29M$4.74M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$1.02M
Total non-current liabilities$25.1M$4.3M$6.16M$8.29M$115.8M
Capital lease obligations$4.29M$8.24M$9.08M$10.6M$5.55M
Total liabilities$61.6M$38.1M$26M$20.3M$131.7M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-424.83M-$-263.52M-$-136.04M-$-75.68M-$-46.78M
Accumulated other comprehensive income (loss)$100K$100K$0.00-$-30K$0.00
Total equity$232.3M$266.6M$49.2M$46.7M-$-46.25M
Total investments$155.2M$189.4M$22.9M$13.6M$550K
Total debt$29M$8.24M$9.08M$10.6M$5.55M
Net debt-$-95.06M-$-88.38M-$-25.57M-$-27.17M-$-70.51M
Cash flow statement
20252024202320222021
Net income-$-161.31M-$-127.48M-$-60.37M-$-28.89M-$-26.35M
Depreciation and amortization$1.8M$2.13M$1.71M$1.05M$590K
Stock-based compensation$10.1M$8.36M$2.22M$930K$7.25M
Change in working capital-$-1.08M$7.86M$3.42M-$-10.33M-$-4.49M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$540K$740K$4.08M$680K$10K
Net cash provided by operating activities-$-153.71M-$-114.25M-$-52.41M-$-36.11M-$-22.16M
Investments in property, plant and equipment-$-10K-$-2.21M-$-620K-$-770K-$-1.29M
Acquisitions, net$70K$0.00$0.00$0.00$0.00
Net cash used for investing activities$40M-$-160.9M-$-8.79M-$-14.1M-$-1.29M
Common stock issued$117.4M$341.2M$650K$170K$30K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$141.2M$337.1M$58.1M$11.9M$72.5M
Net change in cash$27.5M$62M-$-3.08M-$-38.33M$49.1M
Cash at end of period$124.6M$97.2M$35.2M$38.3M$76.6M
Operating cash flow-$-153.71M-$-114.25M-$-52.41M-$-36.11M-$-22.16M
Capital expenditure-$-10K-$-2.21M-$-620K-$-770K-$-1.29M
Free cash flow-$-153.72M-$-116.45M-$-53.03M-$-36.88M-$-23.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kyverna Therapeutics, Inc.

        Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

        CEO
        Warner Biddle
        Employees
        129
        Beta
        1.88

        Explore

        Frequently asked questions

        What is the intrinsic value of Kyverna Therapeutics, Inc. (KYTX)?

        InvestorsCraft does not currently publish an intrinsic value for KYTX. How the IC value is calculated.

        Is KYTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for KYTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.